News Category
Apimeds Pharmaceuticals' subsidiary MindWave Innovations will list its NILA token on the Pionex exchange on Oct. 14, 2026, broadening international ac...
Nutriband Inc. (NASDAQ: NTRB) has raised approximately $1.75 million through warrant exercises, with proceeds earmarked to support the clinical develo...
DuLac Farmaceutici is advancing U.S. retail growth by following up with prospective partners after the 2026 ECRM Vitamin, Weight Management & Sports N...
Nutriband Inc. (NASDAQ: NTRB) has filed a non-provisional utility patent application with the USPTO for improved aversive formulations and coating met...
VERAXA Biotech is implementing FDA-aligned New Approach Methodologies to cut animal testing and speed up development of its next-generation cancer the...
Nutriband Inc. CEO Gareth Sheridan issued a shareholder letter marking the company's fifth anniversary on the Nasdaq Capital Market, detailing progres...
Helus Pharma Inc. has officially changed its legal name from Cybin Inc., signaling its transition toward commercialization of novel mental health trea...
VERAXA Biotech has moved its VXA-222 bispecific antibody-drug conjugate into the next development stage, planning final candidate engineering and prec...
MindWave Innovations, a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc., has signed a 12-month agreement with Flash Sports & Media Holding...
Creative Biolabs has integrated its glycoprotein development and glycan characterization services to help researchers address glycosylation heterogene...
Helus Pharma shareholders approved a legal name change from Cybin Inc. effective Oct. 1 and elected eight directors at the annual and special meeting ...
Nutriband Inc. will let its outstanding warrants expire on September 30, 2026, with no extension or repricing, potentially raising $5.86 million if al...
Peptide Wholesale Supply has extended its HPLC peptide testing protocols to bulk orders of BPC-157, Semaglutide, and Tirzepatide, providing researcher...
Telomir Pharmaceuticals announced that its lead drug candidate Telomir-Zn inhibited growth in human and canine osteosarcoma cell lines, potentially pa...
Kairos Pharma's CEO will present a corporate overview at a major investment conference, highlighting the company's progress in developing ENV-105 to c...
Quantum BioPharma's Lucid-MS, a potential first-in-class treatment for multiple sclerosis, has received FDA clearance for Phase 2 trials, drawing a ne...
Nutriband received a USPTO Notice of Publication for trademarks related to its abuse-deterrent fentanyl patch, moving closer to full trademark protect...
Quantum BioPharma Ltd. has been initiated with a 'Buy' rating and an $8.00 price target by Rodman & Renshaw, highlighting the potential of its lead dr...
Earth Science Tech's acquisition of Zoolzy LLC aims to boost profit margins, broaden access to pharmaceutical ingredients, and enter the veterinary ma...
Italian pharmaceutical company DuLac Farmaceutici accelerates its U.S. expansion by launching products on OneLavi.com and preparing for the 2026 ECRM ...
VERAXA Biotech has moved its VXA-222 bispecific antibody-drug conjugate into preclinical validation, signaling progress in its oncology pipeline and e...
Onco-Innovations has entered a non-binding LOI to acquire an exclusive option on Ifowonco's oral small-molecule LAG-3 inhibitor program, potentially c...
Earth Science Tech's acquisition of Zoolzy LLC aims to cut API costs, boost margins, and expand into veterinary therapeutics, marking a strategic move...
SCHOTT Pharma's parent group's updated climate targets, including a new absolute Scope 3 emissions reduction goal, have been validated by the Science ...
Helus Pharma reported progress in its Phase 3 program for HLP003 in major depressive disorder, with topline data expected in Q4 2026, and provided fin...
VERAXA Biotech AG has advanced its VXA-222 bispecific antibody-drug conjugate into the next development stage and expanded its IP portfolio, underscor...
Tonix Pharmaceuticals announced FDA feedback supporting its planned adaptive Phase 2 study of TNX-4800, a long-acting monoclonal antibody for Lyme dis...
VERAXA Biotech announced the advancement of its bispecific antibody-drug conjugate program VXA-222 after OmniAb completed key discovery work, moving t...
VERAXA Biotech AG has appointed Christoph Erkel, Ph.D., as chief scientific officer to lead development of its proprietary BiTAC platform for solid tu...
NanoViricides announced a $3.8 million registered direct offering to institutional investors, providing capital to advance its broad-spectrum antivira...
VERAXA Biotech AG has appointed Christoph Erkel, Ph.D., as chief scientific officer to lead advancement of its proprietary BiTAC platform for developi...
VERAXA Biotech has received Scientific Advice from Germany's Paul-Ehrlich-Institute supporting its BiTAC(R)-TCE development strategy, reducing regulat...
VERAXA Biotech announced regulatory feedback from Germany's Paul-Ehrlich-Institute for its BiTAC-TCE cancer therapy, providing clarity on development ...
Siegfried appoints Eduardo Montanha as COO to lead its combined Drug Substances and Drug Products operations, enhancing supply performance and operati...
NextPlat Corp plans to acquire a rural pharmacy near Pensacola, Florida for $1.5 million, expanding its PharmcoRx network and introducing new services...
Onco-Innovations Limited announced the successful completion of its analytical reference standard preparation program for ONC010, strengthening its CM...
VERAXA Biotech has initiated cell line development for its lead BiTAC T-cell engager program, partnering with ATUM to support manufacturing and IND-en...
The global sustained release polymers market is projected to grow from USD 3.8 billion in 2026 to USD 7.8 billion by 2036 at a CAGR of 7.4%, driven by...
VERAXA Biotech AG reported progress in its BiTAC platform and growing pharma partner interest, with plans to prioritize BiTAC programs while monetizin...
VERAXA Biotech has begun cell line development for its lead BiTAC T-cell engager program through a collaboration with ATUM, advancing a novel cancer t...
Recent strategic deals in antibody-drug conjugates and T-cell engagers highlight how differentiated technology platforms can attract significant capit...
Ace Therapeutics announces a full-spectrum preclinical pain research platform offering end-to-end services for analgesic drug development, including d...
Medios AG is closing its Aschaffenburg facility and consolidating patient-specific manufacturing to improve efficiency and profitability, affecting 32...
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trials for HLP003 in major depressive disorder, with top-line data ex...
Voyageur Pharmaceuticals has hired Fluor Corporation to conduct feasibility studies for an iodine extraction facility in Oklahoma and an integrated co...
Knight Therapeutics Inc. has repaid the full $60 million drawn from its revolving credit facility in June 2025 to finance the Paladin acquisition, fun...
Voyageur Pharmaceuticals is evaluating three potential locations in the U.S. for its integrated iodine and barium contrast media manufacturing facilit...
Telomir Pharmaceuticals announced peer-reviewed preclinical data demonstrating that its lead candidate Telomir-Zn restored insulin sensitivity and imp...
